Europe Organ Transplant Diagnostics Market: Analysis and Forecast, 2023-2033

List of Tables

“The Europe Organ Transplant Diagnostics Market Expected to Reach $3.35 Billion by 2033.”

Introduction to Europe Organ Transplant Diagnostics Market

In 2023, the Europe organ transplant diagnostics market was valued at $1.16 billion and is expected to reach $3.35 billion by 2033, with a CAGR of 11.15% during the forecast period 2023-2033. Several key factors are propelling growth in this sector, including a surge in the prevalence of chronic diseases resulting in organ failure, a heightened utilization of transplant diagnostics, a growing acceptance of stem cell therapy, an increase in leukemia cases driving demand for transplant diagnostic tests, the benefits derived from the advancement of molecular and genomic technologies in the field of transplant diagnostics, and the existence of favorable regulatory conditions, encompassing reimbursement schemes.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$1.16 Billion
2033 Forecast	$3.35 Billion
CAGR	11.15%

Market Introduction

The Europe organ transplant diagnostics market is experiencing significant growth driven by factors such as the increasing incidence of chronic diseases leading to organ failure. This rise in conditions like kidney, liver, and heart diseases fuels the demand for organ transplants and subsequently, transplant diagnostics. Adoption of transplant diagnostics is on the upswing due to advancements in medical technology and heightened awareness of the importance of pre-transplant compatibility testing. The growing acceptance of stem cell therapy also contributes to the demand for transplant diagnostics. Additionally, the prevalence of leukemia cases necessitates accurate diagnostic tests before bone marrow or stem cell transplantation. Advanced molecular and genomic technologies in transplant diagnostics enhance compatibility assessments. Europe's favorable regulatory environment, including reimbursement schemes, encourages investment in transplant diagnostics by healthcare providers and patients alike. These factors collectively drive growth in the Europe organ transplant diagnostics market, making it a dynamic sector for healthcare advancements.

Market Segmentation:

Segmentation 1: by Country

Germany
U.K.
France
Italy
Spain
Switzerland
Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities.

Competitive Strategy: The key players in the Europe organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the Europe organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

BAG Group GmbH
bioMerieux S.A.
F. Hoffmann-La Roche Ltd.

Eurobio Scientific (Genome Diagnostics B.V.)
Omixon Inc.
QIAGEN N.V.

Product Code: BHP1803SS

Executive Summary

1. Product Definition

1.1. Inclusion and Exclusion Criteria

2. Market Scope

2.1. Key Questions Answered in the Report:

3. Research Methodology

3.1. Organ Transplant Diagnostics Market: Research Methodology
3.2. Data Sources
- 3.2.1. Primary Data Sources
- 3.2.2. Secondary Data Sources
3.3. Market Estimation Model
3.4. Criteria for Company Profiling

4. Overview

4.1. Current Market Scenario
- 4.1.1. For Researchers
- 4.1.2. For Diagnostics
4.2. Market Footprint
4.3. COVID-19 Impact on Market
- 4.3.1. Impact on Operations
- 4.3.2. COVID-19 Impact: Current Scenario of Market
- 4.3.3. Pre- and Post-COVID-19 Impact Assessment
  - 4.3.3.1. Pre-COVID-19 Phase
  - 4.3.3.2. Post-COVID-19 Phase

5. Europe

5.1. Europe
- 5.1.1. Europe Organ Transplant Test Volume, by Transplant Type
- 5.1.2. Market Sizing and Forecast
  - 5.1.2.1. Europe Organ Transplant Diagnostics Market (by Country)
    - 5.1.2.1.1. France
    - 5.1.2.1.2. Spain
    - 5.1.2.1.3. U.K.
    - 5.1.2.1.4. Italy
    - 5.1.2.1.5. Germany
    - 5.1.2.1.6. Switzerland
    - 5.1.2.1.7. Rest-of-Europe

6. Company Profiles

6.1. Overview
6.2. Manufacturers
- 6.2.1. BAG Group GmbH
  - 6.2.1.1. Company Overview
  - 6.2.1.2. Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
  - 6.2.1.3. Product Portfolio
  - 6.2.1.4. Analyst Perception
- 6.2.2. bioMerieux S.A.
  - 6.2.2.1. Company Overview
  - 6.2.2.2. Role of bioMerieux S.A. in the Organ Transplant Diagnostics Market
  - 6.2.2.3. Product Portfolio
  - 6.2.2.4. Financials
  - 6.2.2.5. Recent Developments
  - 6.2.2.6. Analyst Perception
- 6.2.3. Eurobio Scientific (Genome Diagnostics B.V.)
  - 6.2.3.1. Company Overview
  - 6.2.3.2. Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
  - 6.2.3.3. Product Portfolio
  - 6.2.3.4. Analyst Perception
- 6.2.4. F. Hoffmann-La Roche Ltd.
  - 6.2.4.1. Company Overview
  - 6.2.4.2. Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
  - 6.2.4.3. Product Portfolio
  - 6.2.4.4. Financials
  - 6.2.4.5. Recent Developments
  - 6.2.4.6. Analyst Perception
- 6.2.5. Omixon Inc.
  - 6.2.5.1. Company Overview
  - 6.2.5.2. Role of Omixon Inc. in the Organ Transplant Diagnostics Market
  - 6.2.5.3. Product Portfolio
  - 6.2.5.4. Analyst Perception
- 6.2.6. QIAGEN N.V.
  - 6.2.6.1. Company Overview
  - 6.2.6.2. Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
  - 6.2.6.3. Product Portfolio
  - 6.2.6.4. Financials
  - 6.2.6.5. Recent Developments
  - 6.2.6.6. Analyst Perception

Product Code: BHP1803SS

List of Figures

Figure 1: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 2: Organ Transplant Diagnostics Market, Impact Analysis
Figure 3: Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 4: Organ Transplant Diagnostics Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 9: Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
Figure 10: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 11: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
Figure 12: France Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 13: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 14: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 15: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 16: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 17: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 18: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 19: Total Number of Companies Profiled
Figure 20: Organ Transplant Diagnostics Market Overview, Key Companies
Figure 21: BAG Group GmbH: Overall Product Portfolio
Figure 22: bioMerieux S.A.: Overall Product Portfolio
Figure 23: bioMerieux S.A.: Overall Financials, $Million, 2019-2021
Figure 24: bioMerieux S.A.: Net Revenue (by Region), $Million, 2019-2021
Figure 25: bioMerieux S.A.: R&D Expenditure, $Million, 2019-2021
Figure 26: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
Figure 27: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 28: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
Figure 29: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 30: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
Figure 31: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
Figure 32: Omixon Inc.: Overall Product Portfolio
Figure 33: QIAGEN N.V.: Product Portfolio
Figure 34: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 35: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
Figure 36: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 37: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021

List of Tables

Table 1: Key Questions Answered in the Report
Table 2: Europe Organ Transplant Diagnostics Market, Impact Analysis
Table 3: Europe Organ Transplant Test Volume, by Transplant Type, 2021

Europe Organ Transplant Diagnostics Market: Analysis and Forecast, 2023-2033

Description

Table of Contents

List of Tables

Introduction to Europe Organ Transplant Diagnostics Market

Market Introduction

Market Segmentation:

Segmentation 1: by Country

How can this report add value to an organization?

Key Market Players and Competition Synopsis

Some of the prominent names in this market are:

Table of Contents

Executive Summary

1. Product Definition

2. Market Scope

3. Research Methodology

4. Overview

5. Europe

6. Company Profiles

List of Figures

List of Tables